Exploring how CDK1 affects cancer and potential treatments
Official title: Understanding CDK1 Function and Cancer Vulnerabilities
Funded at University of California, San Francisco · NIH-11082306 · Data updated 2026-11-12
This study is looking at a protein called CDK1 to see how it affects aggressive cancers and how blocking it might help improve cancer treatments, using special mouse models to learn more about how this could work while protecting healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 13, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $484,012 |
| NIH project number | 5R01CA266756-03 |
| Project ID | NIH-11082306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with aggressive or metastatic cancers who have not responded well to existing treatments.
✕Less likely to help
Patients with early-stage cancers or those whose tumors do not involve CDK1 may not benefit from this research.
What this research studies
This research investigates the role of CDK1, a protein that regulates the cell cycle, in aggressive and metastatic cancers. The team aims to understand how cancer cells adapt to targeted therapies and how inhibiting CDK1 could lead to better treatment outcomes. By using engineered mouse models, they will explore the effects of CDK1 inhibition on cancer cell behavior and its potential to induce cell death or senescence in tumors while sparing normal cells. This approach seeks to develop new therapeutic strategies that could improve the effectiveness of cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that specifically target cancer cells while minimizing harm to normal cells.
How similar studies have gone: Previous research has shown promise in targeting other cyclin-dependent kinases, suggesting that this approach could yield significant advancements in cancer treatment.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Goga, Andrei — University of California, San Francisco
- Study coordinator: Goga, Andrei
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.